Gastroparesis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST037 MIFTS: 52	Gastroparesis Categories: Gastrointestinal diseases, Metabolic diseases, Muscle diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis ¹² ²⁰ ⁵⁴ ⁴⁴ ¹⁵ ¹⁷ ⁷⁰

Delayed Gastric Emptying ²⁰

Gastroparesis Syndrome ¹²

Gastroparalysis ¹²

Gastric Atonia ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases Muscle diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:11914

ICD9CM ³⁴ 536.3

MeSH ⁴⁴ D018589

NCIt ⁵⁰ C80512

SNOMED-CT ⁶⁷ 235675006

ICD10 ³² K31.84

EFO ¹⁷ EFO_1000948

UMLS ⁷⁰ C0152020

Sources

Summaries for Gastroparesis

GARD : ²⁰ Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride. With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and autonomic neuropathy, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Sodium citrate and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, small intestine and smooth muscle, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷³ Gastroparesis (gastro- from Ancient Greek γαστήρ - gaster, "stomach"; and -paresis, πάρεσις - "partial... more...

Sources

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)

#	Related Disease	Score	Top Affiliating Genes
1	idiopathic gastroparesis	31.5	MRC1 HMOX1 GIP GHSR GHRL
2	autonomic neuropathy	31.2	MLN GAST CCK
3	gastroesophageal reflux	30.8	MLN GHRL GAST CCK
4	pylorospasm	30.7	MLNR MLN
5	diabetic autonomic neuropathy	30.7	MLNR MLN GAST
6	tardive dyskinesia	30.6	DRD2 CYP2D6
7	rumination disorder	30.6	MLNR MLN
8	intestinal obstruction	30.3	MLN GHRL ANO1
9	eating disorder	30.3	GHRL DRD2 CCK
10	bulimia nervosa	30.3	GHRL DRD2 CCK
11	intestinal pseudo-obstruction	30.3	SST MLNR MLN
12	volvulus of midgut	30.3	SST MLNR MLN
13	gastritis	30.2	SST SCT GHRL GAST
14	irritable bowel syndrome	30.1	SST MLN GHRL CCK
15	bilirubin metabolic disorder	30.1	HMOX1 CYP3A4 CYP2D6 ABCB1
16	gastrointestinal system disease	30.1	MLN GHRL GAST CCK
17	atrophic gastritis	30.0	SST GHRL GAST
18	hyperglycemia	30.0	SST GIP GHRL CCK
19	peptic esophagitis	30.0	MLN GAST
20	hernia, hiatus	30.0	MLN GHRL GAST
21	pyloric stenosis	29.9	SST NOS1 MLN GAST
22	bile reflux	29.9	SCT MLN GAST CCK
23	biliary dyskinesia	29.9	SST SCT CCK
24	small cell cancer of the lung	29.8	SST GAST CCK
25	peptic ulcer disease	29.7	SST SCT GHRL GAST
26	gallbladder disease	29.7	SST MLN CCK
27	gilbert syndrome	29.7	HMOX1 CYP3A4 CYP2D6
28	cholelithiasis	29.6	SST GAST CCK
29	sexual disorder	29.6	NOS1 CYP3A4 CYP2D6
30	ileus	29.5	SST MLN GHSR GHRL CCK
31	celiac disease 1	29.5	SCT GHRL GAST CCK
32	alcohol dependence	29.5	TH GHRL DRD2 CCK
33	duodenal ulcer	29.4	SST SCT MLN GAST CCK
34	duodenogastric reflux	29.2	SST SCT MLN GAST CCK
35	migraine with or without aura 1	29.2	SCT NOS1 DRD2 CYP3A4 CYP2D6 CCK
36	acute pancreatitis	29.1	SST SCT CCK
37	dumping syndrome	29.1	SST SCT MLN GIP GHRL GAST
38	diarrhea	29.0	SST SCT MLN GAST CYP3A4 CYP2D6
39	anxiety	28.8	TH GHRL DRD2 CYP3A4 CYP2D6 CCK
40	constipation	28.5	TH SST NOS1 MLNR MLN GHRL
41	body mass index quantitative trait locus 11	28.3	NOS1 KCNH2 HMOX1 GIP GHSR GHRL
42	type 2 diabetes mellitus	28.2	SST SCT NOS1 HMOX1 GIP GHRL
43	diabetes mellitus	27.3	TH SST SCT NOS1 MLN HMOX1
44	brittle diabetes	11.0
45	stomach disease	11.0
46	galactorrhea	10.4	DRD2 CYP2D6
47	neurogenic bowel	10.4	MLN GAST
48	acute diffuse nephritis	10.3	KCNH2 ABCB1
49	type 1 diabetes mellitus	10.3
50	postcholecystectomy syndrome	10.3	MLN GAST CCK

Graphical network of the top 20 diseases related to Gastroparesis:

Sources

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:

ophthalmoplegia; hemiplegia; signs and symptoms, digestive; lassitude; persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00240-S-1	9.68	SST
2	Decreased viability	GR00249-S	9.68	ABCB1 ANO1 GHRL GHSR MLN NOS1
3	Decreased viability	GR00381-A-1	9.68	CYP2D6 GHSR MLN MLNR SCT
4	Decreased viability	GR00381-A-2	9.68	GHSR
5	Decreased viability	GR00381-A-3	9.68	GHSR MLN
6	Decreased viability	GR00386-A-1	9.68	CCK MLN
7	Decreased viability	GR00402-S-2	9.68	ABCB1 ADRA1D CYP2D6 GHSR MLN SCT

MGI Mouse Phenotypes related to Gastroparesis:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.81	ABCB1 ANO1 DRD2 GAST GHRL GHSR
2	homeostasis/metabolism	MP:0005376	9.8	ABCB1 ANO1 CCK DRD2 GAST GHRL
3	no phenotypic analysis	MP:0003012	9.17	ABCB1 CCK DRD2 GHSR NOS1 SST

Sources

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

Esomeprazole

Approved, Investigational

Phase 4

161796-78-7, 161973-10-0, 119141-88-7

9568614 4594

Omeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6

4594

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Cisapride

Approved, Investigational, Withdrawn

Phase 4

81098-60-4

2769 6917698

Tegaserod

Approved, Investigational, Withdrawn

Phase 4

145158-71-0, 189188-57-6

122724

Haloperidol

Approved

Phase 4

52-86-8

3559

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Mosapride

Investigational

Phase 4

112885-41-3

Citrate

Phase 4

Proton Pump Inhibitors

Phase 4

Gastrointestinal Agents

Phase 4

Antacids

Phase 4

Anti-Ulcer Agents

Phase 4

Dopamine Agents

Phase 4

Antiemetics

Phase 4

Dopamine Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Psychotropic Drugs

Phase 4

Serotonin Receptor Agonists

Phase 4

Antipsychotic Agents

Phase 4

Opiate Alkaloids

Phase 4

Haloperidol decanoate

Phase 4

Analgesics

Phase 4

Acetylcholine

Approved, Investigational

Phase 3

51-84-3

187

Prucalopride

Approved

Phase 2, Phase 3

179474-81-8

Nortriptyline

Approved

Phase 3

72-69-5

4543

Domperidone

Approved, Investigational, Vet_approved

Phase 3

57808-66-9

3151

Cholinergic Agents

Phase 3

Antidepressive Agents, Tricyclic

Phase 3

Adrenergic Agents

Phase 3

Antidepressive Agents

Phase 3

Substance P

Phase 3

33507-63-0

44359816

neurokinin A

Phase 3

Lixisenatide

Approved

Phase 1, Phase 2

320367-13-3

Aprepitant

Approved, Investigational

Phase 2

170729-80-3

151165 6918365

Fosaprepitant

Approved

Phase 2

172673-20-0

219090

Levodopa

Approved

Phase 2

59-92-7

6047

Buspirone

Approved, Investigational

Phase 2

36505-84-7

2477

Rifaximin

Approved, Investigational

Phase 2

80621-81-4

6436173 46783403

Erythromycin

Approved, Investigational, Vet_approved

Phase 2

114-07-8

12560

Metoclopramide

Approved, Investigational

Phase 2

364-62-5

4168

Azithromycin

Approved

Phase 2

83905-01-5

55185 447043

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Histamine

Approved, Investigational

Phase 2

51-45-6, 75614-87-8

774

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Loperamide

Approved

Phase 2

53179-11-6

3955

Bismuth subsalicylate

Approved, Vet_approved

Phase 2

14882-18-9

53629521

Methylnaltrexone

Approved

Phase 2

916055-93-1, 83387-25-1

6603824

Acetaminophen

Approved

Phase 2

103-90-2

1983

Interventional clinical trials:

(show top 50) (show all 221)

#	Name	Status	NCT ID	Phase	Drugs
1	Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying	Unknown status	NCT02510976	Phase 4	prucalopride;placebo
2	Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis	Unknown status	NCT02264587	Phase 4	Mosapride;domperidone
3	Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia	Completed	NCT00951431	Phase 4	Esomeprazole;Placebo
4	Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis	Completed	NCT00492622	Phase 4	Immediate-release omeprazole;Delayed-release omeprazole
5	Enterra Therapy Gastric Stimulation System	Terminated	NCT00556166	Phase 4
6	Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options	Terminated	NCT01281540	Phase 4	Cisapride;Placebo
7	Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus	Terminated	NCT01286090	Phase 4	Cisapride;Placebo
8	An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms	Terminated	NCT00390975	Phase 4	Tegaserod
9	Haloperidol vs Conventional Therapy for Gastroparesis	Terminated	NCT02057549	Phase 4	Haloperidol;Conventional Therapy
10	Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis	Withdrawn	NCT01326117	Phase 4	tadalafil
11	A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers	Withdrawn	NCT00944593	Phase 4
12	Effect of Electroacupuncture in Diabetic Patients With Gastroparesis	Unknown status	NCT00227383	Phase 3
13	Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial	Unknown status	NCT01460550	Phase 3
14	Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy	Unknown status	NCT02927886	Phase 3
15	Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study.	Unknown status	NCT01989221	Phase 3	Sancuso®
16	Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)	Completed	NCT00765895	Phase 3	Nortriptyline Hydrochloride;Placebo (for nortriptyline)
17	Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial	Completed	NCT02031081	Phase 2, Phase 3	Prucalopride;Placebo
18	Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis	Completed	NCT02025751	Phase 3	Metoclopramide Nasal Spray;Placebo Nasal Spray
19	Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis	Completed	NCT02025725	Phase 3	Metoclopramide Nasal Spray;Placebo Nasal Spray
20	Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis	Completed	NCT00432835	Phase 3
21	VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis	Recruiting	NCT04028492	Phase 3	Tradipitant;Placebo
22	Dynamic Positron Emission Tomography Imaging With 11C-ER176 to Delineate Macrophage Activation in Diabetic Gastroparesis	Recruiting	NCT04762719	Phase 2, Phase 3	PET/CT Scan with 11C-ER176
23	Treatment Protocol for the Compassionate Use of Domperidone	Recruiting	NCT01696734	Phase 3	Domperidone
24	A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis.	Suspended	NCT00470795	Phase 3
25	Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis	Terminated	NCT03786380	Phase 3	Relamorelin 10 μg
26	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Terminated	NCT03426345	Phase 3	Relamorelin;Placebo
27	A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Terminated	NCT03420781	Phase 3	Relamorelin;Placebo
28	A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Terminated	NCT03383146	Phase 3	Relamorelin;Placebo
29	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Terminated	NCT03285308	Phase 3	Relamorelin;Placebo
30	Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy	Withdrawn	NCT01378884	Phase 3	Domperidone
31	Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy	Withdrawn	NCT00622804	Phase 3
32	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis	Unknown status	NCT02970968	Phase 2	VLY-686 (Tradipitant)
33	Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.	Unknown status	NCT02308254	Phase 1, Phase 2	Lixisenatide;Placebo
34	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis	Completed	NCT01452815	Phase 2	Placebo;10mg TZP-102;20mg TZP-102
35	Acupuncture Treatment for Gastroparesis: a Pilot Study	Completed	NCT01643577	Phase 1, Phase 2
36	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus	Completed	NCT00889486	Phase 2	TZP-102;Placebo
37	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus	Completed	NCT00612014	Phase 2	5% dextrose in water;TZP-101;TZP-101;TZP-101;TZP-101;TZP-101
38	A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis	Completed	NCT01262898	Phase 2	GSK962040 (5 mg tablet);GSK962040 (25 mg tablet);GSK962040 (125 mg tablet);Placebo
39	Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial	Completed	NCT01149369	Phase 2	Aprepitant;Placebo
40	A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis	Completed	NCT02210000	Phase 2	Placebo;Camicinal
41	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying	Completed	NCT01602549	Phase 2	GSK962040 (25 mg tablet);Placebo
42	A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects	Completed	NCT01677338	Phase 2	13C-uracil;99mTc sulfur colloid
43	Pectin Start Early Enteral Nutritional Support in Critically Ill Patients	Completed	NCT02379624	Phase 1, Phase 2	pectin
44	A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis	Completed	NCT03268941	Phase 2	TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
45	Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention	Completed	NCT01557296	Phase 2
46	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis	Completed	NCT01571297	Phase 2	RM-131;Placebo
47	Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis	Completed	NCT01607684	Phase 2
48	A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis	Completed	NCT00861809	Phase 2	GSK962040 25 mg;Placebo;GSK962040 50 mg;GSK962040 1250 mg
49	A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis	Completed	NCT00845858	Phase 2	metoclopramide;Placebo
50	A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis	Completed	NCT01718938	Phase 2	velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :

Cisapride

Metoclopramide

Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Sources

Genetic Tests for Gastroparesis

Sources

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

⁴⁰

Pancreas, Small Intestine, Smooth Muscle, Kidney, Lung, Pituitary, Spinal Cord

Sources

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2717)

#	Title	Authors	PMID	Year
1	Gastroparesis: Quality of Life and Health Care Utilization. ⁶¹ ²⁰	Lacy BE...Heinberg LJ	27775961	2018
2	Psychological controversies in gastroparesis: A systematic review. ⁶¹ ²⁰	Woodhouse S...Knowles SR	28275310	2017
3	Gastroparesis: A Review of Current Diagnosis and Treatment Options. ²⁰ ⁶¹	Stein B...Lacy BE	25874755	2015
4	Gastroparesis: approach, diagnostic evaluation, and management. ⁶¹ ²⁰	Tang DM...Friedenberg FK	21329779	2011
5	Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. ⁶¹ ⁵⁴	Harsch IA...Konturek PC	19082715	2009
6	Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. ⁶¹ ⁵⁴	Firczyk P...Wiecek A	19776684	2009
7	Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. ⁶¹ ⁵⁴	Camilleri M...Odunsi ST	19434096	2009
8	Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. ⁶¹ ⁵⁴	Ejskjaer N...Kosutic G	19298585	2009
9	Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. ⁵⁴ ⁶¹	Ang D...Tack J	19210631	2009
10	No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. ⁶¹ ⁵⁴	Asai S...Tanaka Y	18946177	2009
11	Application of ghrelin to gastrointestinal diseases. ⁵⁴ ⁶¹	Venkova K...Greenwood-Van Meerveld B	18821473	2008
12	Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. ⁵⁴ ⁶¹	Yogo K...Takanashi H	17934842	2008
13	Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. ⁶¹ ⁵⁴	McCallum RW...Investigative Team	17894654	2007
14	Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. ⁵⁴ ⁶¹	Peeters TL	17011824	2006
15	Ghrelin stimulates gastric emptying and hunger in normal-weight humans. ⁶¹ ⁵⁴	Levin F...Naslund E	16772353	2006
16	Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. ⁶¹ ⁵⁴	Gaddipati KV...Parkman HP	16868831	2006
17	Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. ⁶¹ ⁵⁴	Binn M...Poitras P	16426704	2006
18	[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. ⁶¹ ⁵⁴	Zhang Q...Qian JM	16836917	2006
19	Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. ⁵⁴ ⁶¹	Little TJ...Feinle-Bisset C	16492694	2006
20	Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. ⁶¹ ⁵⁴	Murray CD...Emmanuel AV	16085693	2005
21	Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. ⁵⁴ ⁶¹	Tack J...Peeters T	16225494	2005
22	Novel approaches to the treatment of nausea and vomiting. ⁶¹ ⁵⁴	Ladabaum U...Hasler WL	10697661	1999
23	Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. ⁶¹ ⁵⁴	Erbas T...Akalin S	8299441	1993
24	Erythromycin, motilin, and gastroparesis. ⁶¹ ⁵⁴	Yurkowski PJ...Calis KA	1464218	1992
25	Post-operative gastroparesis following carbohydrate loading in a diabetic patient. ⁶¹	How JA...Shafer A	33644283	2021
26	Mechanistic role of antioxidants in rescuing delayed gastric emptying in high fat diet induced diabetic female mice. ⁶¹	Sampath C...Gangula PR	33761597	2021
27	Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis. ⁶¹	Abdelfatah MM...Cai Q	32450364	2021
28	A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection. ⁶¹	Aurora SK...Nguyen L	33793965	2021
29	Safe passage: uncomplicated migration of a 20-mm lumen-apposing metal stent deployed across the pylorus for gastroparesis. ⁶¹	Perumpail RB...Muthusamy VR	33129796	2021
30	The Surgeon's Role in Gastric Electrical Stimulation Therapy for Gastroparesis. ⁶¹	Adams D...Abell T	33236324	2021
31	Epidemiology of gastroparesis: important answers and still more questions. ⁶¹	Dilmaghani S...Camilleri M	32694176	2021
32	Meal-Induced Symptoms in Children with Dyspepsia-Relationships to Sex and the Presence of Gastroparesis. ⁶¹	Febo-Rodriguez L...Shulman RJ	33359472	2021
33	Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities. ⁶¹	Abell TL...Pinkston C	32328893	2021
34	Medical and surgical management of gastroparesis: a systematic review. ⁶¹	Fonseca Mora MC...Rosenthal RJ	33722476	2021
35	What is Missing Before Gastric Peroral Endoscopic Myotomy Can Go Mainstream for Treatment of Gastroparesis? ⁶¹	Khashab MA...Roesch T	32739570	2021
36	Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. ⁶¹	Kuo B...Parkman HP	33811761	2021
37	Comment on: Medical and surgical management of gastroparesis: a systematic review. ⁶¹	Faler B	33423963	2021
38	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. ⁶¹	Ye Y...Ford AC	32493829	2021
39	[Related factors for bile duct infection after surgical treatment of biliary dilatation]. ⁶¹	Wu X...Hong T	33706446	2021
40	Comprehensive Analysis of Adverse Events Associated with Gastric Peroral Endoscopic Myotomy: An International Multicenter Study. ⁶¹	Ichkhanian Y...Khashab MA	32328824	2021
41	Adrenal insufficiency misdiagnosed as diabetic gastroparesis. ⁶¹	Ruiz-Sanchez JG...Gonzalez Perez de Villar N	33783713	2021
42	In-hospital mortality in gastroparesis population and its predictors: A United States-based population study. ⁶¹	Saleem S...Gaduputi V	33732881	2021
43	Controversies in Gastroparesis: Discussing the Sticky Points. ⁶¹	Lacy BE...Cangemi DJ	33767098	2021
44	Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial. ⁶¹	Vosoughi K...Khashab M	33741641	2021
45	Selecting optimal patients with gastroparesis for G-POEM procedure. ⁶¹	Zheng T...Camilleri M	33785556	2021
46	Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. ⁶¹	Gajendran M...McCallum R	33739209	2021
47	Trends and Socioeconomic Health Outcomes of Cannabis Use Among Patients With Gastroparesis: A United States Nationwide Inpatient Sample Analysis. ⁶¹	McCarty TR...Thompson CC	33780213	2021
48	Pyloric dilation with the eosophgeal functional lumen imaging probe in gastroparesis improves gastric emptying, pyloric distensibility, and symptoms. ⁶¹	Murray FR...Pohl D	33771556	2021
49	Impact of Robotic Versus Laparoscopic Pyloroplasty on Short- and Long-term Outcomes in Patients with Gastroparesis. ⁶¹	Bajpai S...Stahl RD	33772401	2021
50	Gastroparesis secondary to pulmonary vein cryoablation: a factor to consider. ⁶¹	Vidal Vilchez B...Martin-Lagos Maldonado A	33222475	2021

Sources

Genes for Gastroparesis

Genes related to Gastroparesis (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MLN	Motilin	Protein Coding	34.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)	17894654 11071469 17011824 (more) 17934842 1464218 9563538
2	MLNR	Motilin Receptor	Protein Coding	26.08	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8299441 10697661
3	GAST	Gastrin	Protein Coding	25.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)	16836917
4	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	21.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16868831 16225494 19082715 (more) 18946177 18821473 16772353 19210631 19434096 16426704 19776684 19298585 17011824 16085693
5	GHSR	Growth Hormone Secretagogue Receptor	Protein Coding	21.1	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16225494 19298585 18946177
6	DRD2	Dopamine Receptor D2	Protein Coding	19.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
7	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	19.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
8	CCK	Cholecystokinin	Protein Coding	19.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16836917
9	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	18.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
10	NOS1	Nitric Oxide Synthase 1	Protein Coding	13.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	ANO1	Anoctamin 1	Protein Coding	12.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	HMOX1	Heme Oxygenase 1	Protein Coding	12.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	MRC1	Mannose Receptor C-Type 1	Protein Coding	12.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	KCNH2	Potassium Voltage-Gated Channel Subfamily H Member 2	Protein Coding	12.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	GIP	Gastric Inhibitory Polypeptide	Protein Coding	12.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	SST	Somatostatin	Protein Coding	12.02	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
17	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
18	TH	Tyrosine Hydroxylase	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
19	ADRA1D	Adrenoceptor Alpha 1D	Protein Coding	11.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	SCT	Secretin	Protein Coding	11.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	HMOX2	Heme Oxygenase 2	Protein Coding	11.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	HRH2	Histamine Receptor H2	Protein Coding	11.23	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)

Sources

Variations for Gastroparesis

Sources

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Sources

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Peptide ligand-binding receptors ⁶⁵ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁵ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁵ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁵ G alpha (i) signalling events ⁶⁵ GPCR ligand binding ⁶⁵ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁶ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁵ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁵ Vasopressin-like receptors ⁶⁵	13.24	SST SCT MLNR MLN GIP GHSR
2	Circadian entrainment ³⁶ Show member pathways Cholinergic synapse ³⁶ Dopaminergic synapse ³⁶ Glutamatergic synapse ³⁶ Growth hormone synthesis, secretion and action ³⁶ Relaxin receptors ⁶⁵ Relaxin signaling pathway ³⁶ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁴	12.81	TH SST NOS1 GHSR GHRL DRD2
3	Glucose / Energy Metabolism ⁴	12.37	KCNH2 CYP3A4 CYP2D6 ABCB1
4	Salivary secretion ³⁶ Show member pathways Gastric acid secretion ³⁶ Pancreatic secretion ³⁶	12.07	SST SCT NOS1 GAST CCK ADRA1D
5	cAMP signaling pathway ³⁶	12.05	SST GIP GHSR GHRL DRD2
6	Statin Pathway - Generalized, Pharmacokinetics ⁶⁰ Show member pathways Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics ⁶⁰ Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics ⁶⁰ Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics ⁶⁰ Clobazam Pathway, Pharmacokinetics ⁶⁰ Diclofenac Metabolic Pathway ¹ Diclofenac Pathway, Pharmacokinetics ⁶⁰ Fluvastatin Pathway, Pharmacokinetics ⁶⁰ Ibuprofen Pathway, Pharmacokinetics ⁶⁰ Pravastatin Pathway, Pharmacokinetics ⁶⁰ Rosiglitazone Pathway, Pharmacokinetics ⁶⁰ Rosuvastatin Pathway, Pharmacokinetics ⁶⁰	11.84	CYP3A4 CYP2D6 ABCB1
7	Clomipramine Pathway, Pharmacokinetics ⁶⁰ Show member pathways Amitriptyline and Nortriptyline Pathway, Pharmacokinetics ⁶⁰ Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 ⁶⁵ Candesartan Pathway, Pharmacokinetics ⁶⁰ Citalopram Pathway, Pharmacokinetics ⁶⁰ Clozapine Pathway, Pharmacokinetics ⁶⁰ Imipramine/Desipramine Pathway, Pharmacokinetics ⁶⁰ Ivacaftor pathway, pharmacokinetics/pharmacodynamics ⁶⁰ Lidocaine metabolism ¹ Metoprolol Pathway, Pharmacokinetics ⁶⁰ Nevirapine Pathway, Pharmacokinetics ⁶⁰ Olanzapine Pathway, Pharmacokinetics ⁶⁰ Paroxetine Pathway, Pharmacokinetics ⁶⁰ Pimozide Pathway, Pharmacokinetics ⁶⁰ Proton Pump Inhibitor Pathway, Pharmacokinetics ⁶⁰ Tacrolimus/Cyclosporine Pathway, Pharmacokinetics ⁶⁰ Venlafaxine Pathway, Pharmacokinetics ⁶⁰ Verapamil Pathway, Pharmacokinetics ⁶⁰ Warfarin Pathway, Pharmacokinetics ⁶⁰	11.81	CYP3A4 CYP2D6 ABCB1
8	Bile secretion ³⁶	11.67	SCT CYP3A4 ABCB1
9	Phenytoin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Atomoxetine Pathway, Pharmacokinetics ⁶⁰ Carbamazepine Pathway, Pharmacokinetics ⁶⁰ Cyclophosphamide Pathway, Pharmacokinetics ⁶⁰ Efavirenz Pathway, Pharmacokinetics ⁶⁰ Sorafenib Pharmacokinetics ⁶⁰	11.48	CYP3A4 CYP2D6 ABCB1
10	Codeine and Morphine Metabolism ¹ Show member pathways Carvedilol Pathway, Pharmacokinetics ⁶⁰ Clopidogrel Pathway, Pharmacokinetics ⁶⁰ Codeine and Morphine Pathway, Pharmacokinetics ⁶⁰ Macrolide Antibiotic Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Tramadol Pharmacokinetics ⁶⁰	11.4	CYP3A4 CYP2D6 ABCB1
11	Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Bosutinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Taxane Pathway, Pharmacokinetics ⁶⁰	11.32	CYP3A4 CYP2D6 ABCB1
12	Erlotinib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Atazanavir Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Dasatinib Pathway, Pharmacokinetics ⁶⁰ Gefitinib Pathway, Pharmacokinetics ⁶⁰	11.12	CYP3A4 CYP2D6 ABCB1
13	Pazopanib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Sunitinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.08	CYP3A4 CYP2D6 ABCB1
14	Drug Induction of Bile Acid Pathway ¹	10.83	CYP3A4 ABCB1
15	Tropisetron Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Ondansetron Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.78	CYP3A4 CYP2D6
16	Sirolimus Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.74	CYP3A4 ABCB1
17	Lamotrigine Pathway, Pharmacokinetics and Pharmacodynamics ⁶⁰	10.73	CYP2D6 ABCB1
18	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.72	CYP3A4 ABCB1
19	Hydrocodone pathway, pharmacokinetics ⁶⁰ Show member pathways Losartan Pathway, Pharmacokinetics ⁶⁰	10.57	CYP3A4 CYP2D6
20	Vinka Alkaloid Pathway, Pharmacokinetics ⁶⁰	10.51	CYP3A4 ABCB1
21	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.23	TH GHSR GHRL DRD2
22	Gastric acid production ¹	9.98	SCT GAST CCK

Sources

GO Terms for Gastroparesis

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 34)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to hypoxia	GO:0001666	9.87	TH NOS1 HMOX1 DRD2
2	memory	GO:0007613	9.81	TH GIP CCK
3	response to hormone	GO:0009725	9.77	NOS1 GHSR GHRL
4	adenylate cyclase-activating adrenergic receptor signaling pathway	GO:0071880	9.66	DRD2 ADRA1D
5	positive regulation of cAMP-mediated signaling	GO:0043950	9.66	SCT GIP
6	oxidative demethylation	GO:0070989	9.65	CYP3A4 CYP2D6
7	neurotransmitter biosynthetic process	GO:0042136	9.65	TH NOS1
8	response to acidic pH	GO:0010447	9.65	SST GIP
9	positive regulation of growth	GO:0045927	9.64	GHSR GHRL
10	synaptic transmission, dopaminergic	GO:0001963	9.64	TH DRD2
11	negative regulation of appetite	GO:0032099	9.63	GHSR CCK
12	response to nicotine	GO:0035094	9.63	TH HMOX1 DRD2
13	response to drug	GO:0042493	9.63	TH SST HMOX1 GIP DRD2 ABCB1
14	adult feeding behavior	GO:0008343	9.62	GHSR GHRL
15	positive regulation of growth hormone secretion	GO:0060124	9.62	GHRL DRD2
16	hyaloid vascular plexus regression	GO:1990384	9.61	TH DRD2
17	heterocycle metabolic process	GO:0046483	9.61	CYP3A4 CYP2D6
18	positive regulation of multicellular organism growth	GO:0040018	9.61	GHSR GHRL DRD2
19	drug catabolic process	GO:0042737	9.59	CYP3A4 CYP2D6
20	growth hormone secretion	GO:0030252	9.58	GHSR GHRL
21	monoterpenoid metabolic process	GO:0016098	9.58	CYP3A4 CYP2D6
22	negative regulation of insulin secretion	GO:0046676	9.58	GHSR GHRL DRD2
23	positive regulation of eating behavior	GO:1904000	9.56	GHSR GHRL
24	response to nutrient levels	GO:0031667	9.56	TH SCT GIP GHRL
25	regulation of transmission of nerve impulse	GO:0051969	9.55	GHSR GHRL
26	positive regulation of appetite	GO:0032100	9.54	GHSR GHRL
27	regulation of gastric motility	GO:1905333	9.52	GHSR GHRL
28	positive regulation of small intestine smooth muscle contraction	GO:1904349	9.51	GHSR GHRL
29	exogenous drug catabolic process	GO:0042738	9.5	NOS1 CYP3A4 CYP2D6
30	isoquinoline alkaloid metabolic process	GO:0033076	9.49	TH CYP2D6
31	alkaloid catabolic process	GO:0009822	9.48	CYP3A4 CYP2D6
32	positive regulation of small intestinal transit	GO:0120058	9.37	GHSR GHRL
33	G protein-coupled receptor signaling pathway	GO:0007186	9.36	SST SCT MLNR MLN GIP GHSR
34	postsynaptic modulation of chemical synaptic transmission	GO:0099170	9.13	GHSR GHRL DRD2

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity	GO:0016491	9.8	TH NOS1 HMOX1 CYP3A4 CYP2D6
2	monooxygenase activity	GO:0004497	9.5	TH CYP3A4 CYP2D6
3	hormone binding	GO:0042562	9.37	MLNR GHSR
4	dopamine binding	GO:0035240	9.26	TH DRD2
5	heme binding	GO:0020037	9.26	NOS1 HMOX1 CYP3A4 CYP2D6
6	hormone activity	GO:0005179	9.17	SST SCT MLN GIP GHRL GAST
7	tetrahydrobiopterin binding	GO:0034617	9.16	TH NOS1

Sources

Sources for Gastroparesis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 20-May-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Gastroparesis

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Classifications:

External Ids:

Summaries for Gastroparesis

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Gastroparesis:

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Gastroparesis:

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

Publications for Gastroparesis

Articles related to Gastroparesis:

Genes for Gastroparesis

Genes related to Gastroparesis (0 elite genes):

Variations for Gastroparesis

Expression for Gastroparesis

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

GO Terms for Gastroparesis

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

Sources for Gastroparesis

Inferred drug relations via UMLS ⁷⁰ / NDF-RT ⁵¹ :